Literature DB >> 19169690

Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents.

Hubertus Pietsch1, Philipp Lengsfeld, Gregor Jost, Thomas Frenzel, Joachim Hütter, Martin A Sieber.   

Abstract

Several publications suggest a potential association between the administration of Gadolinium-based contrast agents (GBCAs) and the onset of a rare but serious disease, Nephrogenic Systemic Fibrosis (NSF). The aim of this study was to determine the elimination time-course of Gadolinium (Gd) from skin tissue after application of GBCAs in rats. Seven different marketed GBCAs were injected on five consecutive days at a dose of 2.5 mmol/kg bodyweight into the tail vein of Han-Wistar rats and the Gd concentrations were determined by Inductively Coupled Plasma Mass Spectrometry (ICP-MS) in skin biopsies taken at various time-points up to a year after the last injection. Most of the administered Gd was eliminated from the skin within a time-period of about 2 months. However, the repeated administration of linear GBCAs resulted in long-term retention of a small portion of the administered Gd in the skin tissue of rats, with substantially higher values observed in animals treated with non-ionic linear agents than in those that received ionic linear GBCAs. Following treatment with macrocyclic GBCAs, Gd values in the skin were in the same range as observed in the controls from day 24 post-injection onwards. In summary, we observed a correlation between the complex stability of GBCAs and the amount of residual Gd in the skin up to a year after application of GBCAs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19169690     DOI: 10.1007/s00330-008-1259-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  19 in total

1.  Summary of preclinical safety evaluation of gadoteridol injection.

Authors:  R A Soltys
Journal:  Invest Radiol       Date:  1992-08       Impact factor: 6.016

2.  The relationship between thermodynamics and the toxicity of gadolinium complexes.

Authors:  W P Cacheris; S C Quay; S M Rocklage
Journal:  Magn Reson Imaging       Date:  1990       Impact factor: 2.546

3.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

4.  Tolerance of extracellular contrast agents for magnetic resonance imaging.

Authors:  H J Weinmann; W R Press; H Gries
Journal:  Invest Radiol       Date:  1990-09       Impact factor: 6.016

5.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

Authors:  Peter Marckmann; Lone Skov; Kristian Rossen; Anders Dupont; Mette Brimnes Damholt; James Goya Heaf; Henrik S Thomsen
Journal:  J Am Soc Nephrol       Date:  2006-08-02       Impact factor: 10.121

6.  Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media.

Authors:  N R Puttagunta; W A Gibby; V L Puttagunta
Journal:  Invest Radiol       Date:  1996-10       Impact factor: 6.016

7.  Toxicological assessment of gadoversetamide injection (OptiMARK), a new contrast-enhancement agent for use in magnetic resonance imaging.

Authors:  J H Wible ; C M Troup; M R Hynes; K P Galen; J R MacDonald; S J Barco; J K Wojdyla; M P Periasamy; M D Adams
Journal:  Invest Radiol       Date:  2001-07       Impact factor: 6.016

8.  Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.

Authors:  Marc Port; Jean-Marc Idée; Christelle Medina; Caroline Robic; Monique Sabatou; Claire Corot
Journal:  Biometals       Date:  2008-03-15       Impact factor: 2.949

9.  Gadolinium determination in tissue samples by inductively coupled plasma mass spectrometry and inductively coupled plasma atomic emission spectrometry in evaluation of the action of magnetic resonance imaging contrast agents.

Authors:  E M Frame; E E Uzgiris
Journal:  Analyst       Date:  1998-04       Impact factor: 4.616

10.  Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.

Authors:  Martin A Sieber; Philipp Lengsfeld; Thomas Frenzel; Sven Golfier; Heribert Schmitt-Willich; Fred Siegmund; Jakob Walter; Hanns-Joachim Weinmann; Hubertus Pietsch
Journal:  Eur Radiol       Date:  2008-06-11       Impact factor: 5.315

View more
  19 in total

1.  Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far?

Authors:  Sameh K Morcos
Journal:  Eur Radiol       Date:  2010-09-17       Impact factor: 5.315

2.  Pathophysiology of nephrogenic systemic fibrosis: A review of experimental data.

Authors:  Sameh K Morcos; John Haylor
Journal:  World J Radiol       Date:  2010-11-28

Review 3.  The Impact of Excess Ligand on the Retention of Nonionic, Linear Gadolinium-Based Contrast Agents in Patients With Various Levels of Renal Dysfunction: A Review and Simulation Analysis.

Authors:  John P Prybylski; Michael Jay
Journal:  Adv Chronic Kidney Dis       Date:  2017-05       Impact factor: 3.620

4.  Total gadolinium tissue deposition and skin structural findings following the administration of structurally different gadolinium chelates in healthy and ovariectomized female rats.

Authors:  Yì-Xiáng J Wáng; Joseph Schroeder; Heiko Siegmund; Jean-Marc Idée; Nathalie Fretellier; Gaëlle Jestin-Mayer; Cecile Factor; Min Deng; Wei Kang; Sameh K Morcos
Journal:  Quant Imaging Med Surg       Date:  2015-08

Review 5.  Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement.

Authors:  Carlo C Quattrocchi; Joana Ramalho; Aart J van der Molen; Àlex Rovira; Alexander Radbruch
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

6.  Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol.

Authors:  Dragan A Stojanov; Aleksandra Aracki-Trenkic; Slobodan Vojinovic; Daniela Benedeto-Stojanov; Srdjan Ljubisavljevic
Journal:  Eur Radiol       Date:  2015-06-25       Impact factor: 5.315

Review 7.  Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.

Authors:  Dragan Stojanov; Aleksandra Aracki-Trenkic; Daniela Benedeto-Stojanov
Journal:  Neuroradiology       Date:  2016-02-12       Impact factor: 2.804

Review 8.  T1 hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition?

Authors:  Nigel Hoggard; Giles H Roditi
Journal:  Br J Radiol       Date:  2016-10-19       Impact factor: 3.039

9.  Detection of gadolinium deposition in cortical bone with ultrashort echo time T1 mapping: an ex vivo study in a rabbit model.

Authors:  Kaixuan Zhao; Shisi Li; Peiwei Yi; Yihao Guo; Qinqin Yu; Cuiling Zhu; Qianjin Feng; Jiang Du; Xiaodong Zhang; Yanqiu Feng
Journal:  Eur Radiol       Date:  2020-09-14       Impact factor: 5.315

Review 10.  Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.

Authors:  Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Marie-France Bellin; Michele Bertolotto; Georg Bongartz; Olivier Clement; Peter Leander; Gertraud Heinz-Peer; Peter Reimer; Fulvio Stacul; Aart van der Molen; Judith A W Webb
Journal:  Eur Radiol       Date:  2012-08-04       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.